TPX2 and breast carcinoma: Kahl et al. (Kahl et al. 2022) experimentally explored TPX2 expression in 3952 breast cancer cases and observed markedly increased expression of TPX2 in tumor tissues, and its high expression was detrimental to the OS of patients, suggesting that TPX2 could be used as a therapeutic target.